In Situ Programming of Armored CAR‐Macrophages by Microneedle‐Mediated Gene Delivery for Melanoma Immunotherapy
Advanced Materials · 18.11.2026
DOI: 10.1002/adma.75787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 18.11.2026. Verfasst von Juhyeong Hong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, Seoul, Republic of Korea. Die Arbeit nennt 23 Literaturangaben. Gefördert von: National Research Foundation of Korea, Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Ministry of Health and Welfare, Brain Korea 21 Fostering Outstanding Universities for Research.
Abstract (Originalsprache)
Despite clinical advances in CAR‐T therapy and immune checkpoint blockade, effective immunotherapy for solid tumors remains limited by restricted immune‐cell access and an immunosuppressive tumor microenvironment. Chimeric antigen receptor macrophages (CAR‐M) provide an alternative strategy by combining antigen‐directed myeloid programming with local immune remodeling. A self‐locking microneedle platform incorporating mannose‐modified nanoparticles (MNPs) enables localized in situ programming of CAR‐expressing macrophages at melanoma sites. The platform co‐delivers a tumor‐antigen‐directed CAR and a hypoxia‐responsive anti‐PD‐L1 single‐chain variable fragment (scPD‐L1). Initial studies in B16F10‐OVA tumors establish antigen‐dependent CAR activity and coordinated local immune remodeling. Therapeutic efficacy is subsequently evaluated in parental B16F10 tumors using an endogenous tyrosinase‐related protein 1 (TYRP1)‐directed CAR. MNP(TYRP1/scPD‐L1) microneedles delay tumor progression, prolong survival, and promote coordinated myeloid and CD8 + T‐cell responses, while providing lower terminal tumor burden, greater local surface CAR + tumor‐associated macrophage abundance, and reduced systemic exposure compared with dose‐matched intratumoral administration. Reciprocal depletion further shows that CAR‐programmed macrophages contribute to the antigen‐directed myeloid response, whereas CD8 + T cells are major downstream effectors required for maximal and sustained tumor control. These findings establish a localized transcutaneous strategy that coordinates antigen‐directed myeloid programming with adaptive antitumor immunity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, Seoul, Republic of Korea.
- Department of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, BK 21 Plus Future Biopharmaceutical Human Resources Training and Research Team, Hanyang University, Seoul, Republic of Korea.
- Cursus Bio Inc., Seoul Bio Hub, Seoul, Republic of Korea.
ORCID-Profile: Juhyeong Hong, Jaehyun Kim, Yong-Hee Kim
Förderung
- National Research Foundation of Korea
- Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Ministry of Health and Welfare
- Brain Korea 21 Fostering Outstanding Universities for Research
Zitieren
APA
Hong, J., Lim, H., Kim, K., Kim, S., Kim, J., Lahiji, S. F., & Kim, Y. H. (2026). In Situ Programming of Armored CAR‐Macrophages by Microneedle‐Mediated Gene Delivery for Melanoma Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.75787
Vancouver
Hong J, Lim H, Kim K, Kim S, Kim J, Lahiji SF, et al. In Situ Programming of Armored CAR‐Macrophages by Microneedle‐Mediated Gene Delivery for Melanoma Immunotherapy. Advanced Materials. 2026. doi:10.1002/adma.75787
BibTeX
@article{Hong2026,
author = {Hong, Juhyeong and Lim, Hanseok and Kim, Kyungdong and Kim, Sangjin and Kim, Jaehyun and Lahiji, Shayan Fakhraei and Kim, Yong-Hee},
title = {In Situ Programming of Armored CAR‐Macrophages by Microneedle‐Mediated Gene Delivery for Melanoma Immunotherapy},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.75787}
}
EUVIMED